Exploring new therapies for systemic sclerosis complications
Clinical-Translational Studies in Skin, Lung, and Vascular Complications in Systemic Sclerosis
This study is looking for new treatments for people with systemic sclerosis by exploring the disease's causes and finding helpful markers, so that patients can eventually benefit from better and more targeted therapies.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pittsburgh at Pittsburgh NIH-funded |
| Lab location | 1 site (Pittsburgh, United States) |
| Project ID | NIH-10929327 on NIH RePORTER |
What this research studies
This research aims to discover new therapies for patients with systemic sclerosis (SSc) by utilizing biomarker tools and translational research observations. The approach includes understanding the disease's pathogenic pathways, identifying biomarkers for SSc complications, and applying bioinformatics to interpret data. The research also focuses on developing targeted therapeutics to address the complexities of SSc, which is characterized by its heterogeneity and limited understanding. Patients may benefit from innovative treatments that arise from this comprehensive investigation.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with systemic sclerosis, particularly those experiencing complications related to the disease.
Not a fit: Patients with other autoimmune diseases or those not diagnosed with systemic sclerosis may not receive any benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new and effective therapies for patients suffering from systemic sclerosis.
How similar studies have performed: Previous research has shown promise in using biomarker tools and translational approaches for other autoimmune diseases, indicating potential success for this novel investigation.
Where this research is happening
Pittsburgh, United States
- University of Pittsburgh at Pittsburgh — Pittsburgh, United States (Active)
Researchers
- Principal investigator: Lafyatis, Robert a. — University of Pittsburgh at Pittsburgh
- Study coordinator: Lafyatis, Robert a.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.